Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma

NCT04814108 is registered in ClinicalTrials.gov with K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc as lead sponsor.

NCT NCT04814108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04814108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma
Lead sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Completed
Start date
July 28, 2021
Completion date
October 22, 2025
Enrollment
92 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

uterine serous carcinoma